MARKET WIRECNBC • 3h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why IDXG Stock surged +15.56% Today — RQD Quant Desk Flash
$5.72 +15.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $5.87
Interpace Biosciences Inc. (IDXG) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C+ • HOLD / WATCH
Cap $23.2M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $5.87 (+2.61%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 14.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 66/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.4% avg 90D alpha vs SPY • 56.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C · Rk B-
Each axis scored 0–20
12M PRICE TARGET CONE+3.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IDXG)Realized 20D OHLCV Swing Band: ±9.4%
Deterministic 5-Pillar Attribution (66/100 Composite)
🔍 WHY IDXG SCORES 66/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (23% of score)
FRED Regime × Technicals: 70% of 52W Range • RSI-14 at 50 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (23% of score)
SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)
▼ #1 Drag / Risk Factor: Cash Engine Quality9/20 pts (-11 pt drag)
Capital intensity & 10.5% operating margin leave 11 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B+$6.00-14.2% Next Q
74
Q2 (-2Q)Grade B$5.15+26.2% Next Q
71
Q3 (-1Q)Grade B-$6.50-12% Next Q
69
CurrentGrade C+$5.72+1.4% Hist 90D α
66
Trajectory: B+ (74) → C+ (66)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the IDXG Bull Thesis Could Fail
Even with a 66/100 (C+) score, IDXG faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 59.8% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($5.70) or 200D SMA ($2.74) invalidates the momentum regime and cuts Target Base ($5.93) toward Bear Floor ($4.63).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $IDXG• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IDXG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IDXG Stock surged +15.56% Today — RQD Quant Desk Flash
Interpace Biosciences Inc. (IDXG) surged +15.56% to $5.72, trading at 70% of its 52-week range ($0.81 – $7.8). Solid 62% profit margin (16% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 70% of its 52-week range ($0.81 – $7.8) with RSI-14 at 50 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.4% around $5.72 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C+ (Hold) backed by 62.3% gross margin and $5.5M annual free cash flow.
Live IDXG Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (IDXG Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IDXG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +188.89%▼ DESCENDING CHANNEL
2026-10-30O $5.59H $5.72L $5.59C $5.72VOL 500
RES: $6.33SUP: $0.86SMA50: $5.70SMA200: $2.74
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IDXG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
-11.1%/yr Implied 5Y Growth
vs. -17.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on IDXG today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IDXG. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IDXG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IDXG)
Industrials Rank #109 of 485
⚔️ JBDI vs IDXG Full Matrix →
1. Head-to-Head Industrials Peer Comparison (IDXG vs. JBDI, BHST, RML, STKE)
Industry: Diversified Equities (43 Tracked Issuers)Across 485 tracked Industrials securities in the Roarable RQD universe, Interpace Biosciences Inc. (IDXG) ranks #109 by composite RQD confidence (66/100, grade C+) and #430 by equity capitalization ($23.2M). Within this direct 5-issuer industry benchmark cohort, IDXG leads on earnings valuation at N/A trailing P/E, while IDXG leads on capital efficiency and profitability with 16.2% ROIC and 62.3% gross margin. IDXG currently leads its immediate peer cohort in composite quantitative strength at 66/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IDXG
ACTIVE
Interpace Biosciences Inc. | C+ | 66/100 | — | 62.3% | 16.2% | +15.56% | $23.2M | Benchmark Subject |
| JBDI JBDI Holdings Limited | D | 45/100 | — | 49.9% | — | +0.42% | $22.9M | /jbdi-vs-idxg → |
| BHST BioHarvest Sciences Inc. | E | 34/100 | — | 59.3% | -35.0% | -5.68% | $37.6M | /bhst-vs-idxg → |
| RML Resolution Minerals Ltd | D+ | 58/100 | — | — | — | -1.99% | $44.1M | /rml-vs-idxg → |
| STKE Sol Strategies Inc. | D | 50/100 | — | — | — | -1.16% | $50.5M | /stke-vs-idxg → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001054102In its most recent audited fiscal period (FY2025, filed 2025-12-31), Interpace Biosciences Inc. (IDXG) reported GAAP revenue of $38.7M (-17.5% vs. FY2024 revenue of $46.9M , and -3.3% cumulative change since FY2023) , GAAP net income of $24.6M, operating cash flow of $5.8M, and free cash flow of $5.5M (+45.2% YoY). On the balance sheet, IDXG closed FY2025 with $33.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $38.7M | $24.6M | $5.8M | $5.5M | $33.8M | — |
| FY2024 (FY) | 2024-12-31 | $46.9M | $6.7M | $4.6M | $3.8M | $14.8M | — |
| FY2023 (FY) | 2023-12-31 | $40.0M | $2.0M | $3.8M | $3.8M | — | — |
3. IDXG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IDXG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Interpace Biosciences Inc. (NASDAQ: IDXG) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 66/100 at a spot price of $5.72 (+15.56% 1D, market cap $23.2M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 15/20. Across 485 tracked Industrials issuers, IDXG ranks #109 in composite RQD confidence.
How does IDXG compare to JBDI and BHST in the Industrials sector?
Within the Industrials sector (Diversified Equities), IDXG carries a Roarable C+ (66/100 RQD), trailing P/E of N/A, gross margin of 62.3%, and ROIC of 16.2%. By comparison, JBDI (JBDI Holdings Limited) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $22.9M) and BHST (BioHarvest Sciences Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $37.6M). Among the 5-stock peer group, IDXG leads on earnings multiple (N/A) while IDXG leads on capital efficiency (16.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IDXG?
Per IDXG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001054102), Interpace Biosciences Inc. generated $38.7M in revenue (-17.5% YoY), $24.6M in net income, and $5.5M in free cash flow against $33.8M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IDXG trading relative to its 50-day, 200-day, and 52-week technical levels?
IDXG last traded at $5.72 (+15.56% on volume of 5,107 shares), positioning the stock +0.35% above its 50-day simple moving average ($5.70) and +108.76% above its 200-day simple moving average ($2.74). Across its 52-week range of $0.81 to $7.80, IDXG sits at the 70.2% percentile with a 14-day RSI of 50.0 (NEUTRAL RANGE) and an implied next-earnings move of ±9.4% ($5.18 to $6.26).
IDXG Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is IDXG stock moving today?
Why IDXG Stock surged +15.56% Today — RQD Quant Desk Flash. Solid 62% profit margin (16% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.